Back to top
more

Cue Biopharma (CUE)

(Delayed Data from NSDQ)

$0.67 USD

0.67
327,697

-0.06 (-7.94%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $0.68 +0.01 (1.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of -21.43% and 78.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of 0% and 12.19%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

by Zacks Equity Research

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ontrak, Inc. (OTRK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ontrak (OTRK) delivered earnings and revenue surprises of -13.46% and 1.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 2.90% and 6.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of 0% and 5.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -5.45% and 18.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks

by Zacks Equity Research

Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?